NCM·Healthcare·$85M·#314 / 520 in Healthcare
RLYB Rallybio Corporation
38HIGH RISK
CATEGORY BREAKDOWN
GROWTH56
QUALITY0
STABILITY62
VALUATION0
GOVERNANCE52
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+34.9%
56
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
13 months
43
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
0.3%
100
< 25% strong
Price / Sales
Market cap relative to trailing revenue
98.5x
0
< 3x strong
Rule of 40
Growth rate plus operating margin
-3819
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
4.2%
34
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+1.8%
89
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE RLYB WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when RLYB's score changes by 5+ points.
DATA INFO
Last updated: Aug 1, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.